Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma | Zendy

Sheng-Hsiang Yang | Zendy; Liang-Tsai Hsiao | Zendy; Tzeon-Jye Chiou | Zendy; Ching-Fen Yang | Zendy; Yuan-Bin Yu | Zendy; ChunYu Liu | Zendy; Jyh-Pyng Gau | Zendy; Liu H | Zendy; PoMin Chen | Zendy; ChengHwai Tzeng | Zendy

Open Access

Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma

Author(s) -

Sheng-Hsiang Yang,

Liang-Tsai Hsiao,

Tzeon-Jye Chiou,

Ching-Fen Yang,

Yuan-Bin Yu,

ChunYu Liu,

Jyh-Pyng Gau,

Liu H,

PoMin Chen,

ChengHwai Tzeng

Publication year - 2015

Publication title -

journal of the chinese medical association

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.535

H-Index - 42

eISSN - 1728-7731

pISSN - 1726-4901

DOI - 10.1016/j.jcma.2015.02.005

Subject(s) - medicine , rituximab , lymphoma , radiation therapy , induction therapy , oncology , monoclonal , radiology , monoclonal antibody , antibody , immunology , chemotherapy

Primary mediastinal large B-cell lymphoma (PMBCL) is a rare malignancy that has been reported in young individuals, especially young women. Patients with PMBCL commonly receive rituximab induction. This single-institution study was designed to analyze the clinical benefits of rituximab induction and its impact on postinduction treatments (PITs), especially radiotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research